Abstract A 63 year old women developed progressive shortness of breath, pulmonary hypertension, and respiratory failure and died from pulmonary fibrosis 45 years after thoracic fistulography with Thorotrast.
system.' Except for isolated cases of lung cancer,26 the lungs have not been considered to be specifically injured by Thorotrast. We report a case of lung fibrosis causing death 45 years after thoracic fistulography with Thorotrast.
Case report At the age of 18, in 1940 during the second world war, our patient sustained extensive shrapnel wounds to the back of her chest. She required drainage of bilateral haemothoraces and during her hospital stay an unknown amount of Thorotrast was injected to outline thoracic fistulas. She recovered fully and led a normal life in Canada from 1945 until 1977 . She smoked about 20 cigarettes a day and worked as a bank employee. Since 1978, however, she had increasing dyspnoea and reduced effort tolerance and in 1983 was admitted to hospital in Vancouver with severe breathlessness and hypoxaemic respiratory failure. Chest radiographs showed transient alveolar infiltrates and Kerley B lines, consistent with pulmonary oedema.
On her return to Belgium in September 1983 physical examination showed bilateral posterior thoracic scars and inspiratory basal crackles. Chest radiographs showed radioopaque tracks of blind fistulas in the mid zones and a diffuse reticular pattern predominant in the lower lung fields (fig 1) pigment) and in the walls of small vessels in both giant cells and endothelial cells, suggesting that they had passed through the vessels. 
Discussion
Thorotrast has been associated with long term complications, particularly malignant tumours developing either near injection sites (thorotrastomas) or in the reticuloendothelial system. Thorium dioxide is retained in the reticuloendothelial system, from which it emits alpha particles in great quantities over prolonged periods."' Fibrosis has also been found frequently near the injection sites as a result of extravasation in subcutaneous tissue8 as well as in the reticuloendothelial system. Thus liver cirrhosis, fibrosis of the spleen, and myelofibrosis may occur. 9 Our patient died from lung fibrosis 45 years after the injection of Thorotrast into her thoracic fistulas. Several features are consistent with a causal role of thorium in the induction of her lung fibrosis. The first is the presence of abundant thorium dioxide particles in the lung sections, particularly in the fibrous zones and in the vascular walls. Histologically, the perivascular fibrosis suggests that the offending agent may have entered the lungs via the bloodstream. It is conceivable that radioactive thorium particles within the endothelial cells of the pulmonary capillaries could lead to modification of their permeability, and thus explain the episodes of non-cardiogenic pulmonary oedema. Lung fibrosis may result from chronic or recurrent pulmonary oedema, as in mitral stenosis.'°I n addition, radiation is a well known cause of lung fibrosis and Thorotrast has been implicated in the development of fibrosis in other organs. Determination of the radiation dose to a target tissue is difficult,5"' and calculation of the total cumulative radiation dose to the lungs is impossible because the initial injected doses and the change in thorium dioxide concentration in the lung parenchyma over 45 years are not known. The doses to tissues adjacent to the surface of Thorotrast aggregates, however, are considered to be very high,'2 and this is supported by the appearances of the autoradiographs of the lung sections from our patient.
There were no occupational, environmental, or drug related causes for lung fibrosis and no apparent systemic disease. We infer therefore that Thorotrast was the cause of the lung fibrosis. We can find no previous reports of lung fibrosis due to Thorotrast despite the many thousands of patients injected with it.239 The type of injection (thoracic fistulography), however, appears to have been rare. Among 168 patients described by Boyd et al3 who received Thorotrast, 141 had intra-arterial injections and 27 cerebral ventricular or subarachnoid injections.
Particles were found in the liver and spleen of our patient and microscopy of the lung tissue suggested transendothelial passage. Probably thorium particles were resorbed by lymphatics from the tissue around the fistulas and passed into the bloodstream. The presence of thorium particles in the blood vessel walls suggests that this "embolisation" process was continuing at the time of lung biopsy, which is consistent with the episodes of pulmonary oedema that characterised our patient's illness. It is also possible that thoracic lymphatic drainage was impaired by adhesions between the parietal and visceral pleura, and by obstruction due to thorium induced fibrosis'3 in thoracic lymph nodes, thus reducing the clearance of lung particles and increasing their retention in the interstitium of the lung.
We conclude that lung fibrosis should be considered as a late complication of thoracic fistulography with Thorotrast.
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